TY - JOUR
T1 - Tackling the challenges of product development through a collaborative rare disease network
T2 - The foundation fighting blindness consortium
AU - Foundation Fighting Blindness Consortium Investigator Group
AU - Durham, Todd A.
AU - Duncan, Jacque L.
AU - Ayala, Allison R.
AU - Birch, David G.
AU - Cheetham, Janet K.
AU - Ferris, Frederick L.
AU - Hoyng, Carel B.
AU - Pennesi, Mark E.
AU - Sahel, José Alain
N1 - Funding Information:
Supported by funds from the Foundation Fighting Blindness, Columbia, Maryland. David Birch is supported by NIH Grant EY009076. Jacque Duncan is supported by an unrestricted Grant from Research to Prevent Blindness to UCSF and NIH-NEI core Grant NEI-EY002162. Mark Pennesi is supported by an unrestricted Grant from RPB to Casey Eye Institute and a core Grant NIH P30EY010572. José-Alain Sahel is supported by an unrestricted Grant from RPB to UPMC Eye Center, a core Grant NIH P30-EY08098, the ERC Synergy HELMHOLTZ Grant and the IHU FOReSIGHT Grant.
Publisher Copyright:
© 2021 The Authors.
PY - 2021
Y1 - 2021
N2 - The Foundation Fighting Blindness, a 501(c)(3) nonprofit organization, established an international consortium of inherited retinal disease specialists in 2016, with a mission to accelerate the development of treatments for rare, inherited retinal degenerations, such as retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis, Usher syndrome, choroideremia, and achromatopsia. The Consortium accomplishes its mission by evalu-ating novel outcome measures, sharing standardized study protocols and datasets, and disseminating findings. Having established research infrastructure in the first 3 years, including 39 global research sites, the network is now poised to expand its infrastructure for trials of new therapies in partnership with industry. This model represents an innova-tive approach to overcome challenges of therapeutic development for rare diseases.
AB - The Foundation Fighting Blindness, a 501(c)(3) nonprofit organization, established an international consortium of inherited retinal disease specialists in 2016, with a mission to accelerate the development of treatments for rare, inherited retinal degenerations, such as retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis, Usher syndrome, choroideremia, and achromatopsia. The Consortium accomplishes its mission by evalu-ating novel outcome measures, sharing standardized study protocols and datasets, and disseminating findings. Having established research infrastructure in the first 3 years, including 39 global research sites, the network is now poised to expand its infrastructure for trials of new therapies in partnership with industry. This model represents an innova-tive approach to overcome challenges of therapeutic development for rare diseases.
KW - Consortium
KW - Genetic
KW - Infrastructure
KW - Inherited retinal degenerations
KW - Natural history
KW - Outcome measures
KW - Retinitis pigmentosa
UR - http://www.scopus.com/inward/record.url?scp=85105512077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105512077&partnerID=8YFLogxK
U2 - 10.1167/tvst.10.4.23
DO - 10.1167/tvst.10.4.23
M3 - Article
AN - SCOPUS:85105512077
SN - 2164-2591
VL - 10
JO - Translational Vision Science and Technology
JF - Translational Vision Science and Technology
IS - 4
M1 - 23
ER -